In Silico Analysis of Bioactive Peptides Produced from Underutilized Sea Cucumber By-Products—A Bioinformatics Approach

Tharindu R. L. Senadheera 1, Abul Hossain 1, Deepika Dave 1,2,* and Fereidoon Shahidi 1,*

1 Department of Biochemistry, Memorial University of Newfoundland, St. John’s, NL A1C 5S7, Canada
2 Marine Bioprocessing Facility, Centre of Aquaculture and Seafood Development, Marine Institute, Memorial University, St. John’s, NL A1C 5R3, Canada
* Correspondence: deepika.dave@mi.mun.ca (D.D.); fshahidi@mun.ca (F.S.)

Abstract: Bioinformatic tools are widely used in predicting potent bioactive peptides from food derived materials. This study was focused on utilizing sea cucumber processing by-products for generating antioxidant and ACE inhibitory peptides by application of a range of in silico techniques. Identified peptides using LC-MS/MS were virtually screened by PepRank technique followed by in silico proteolysis simulation with representative digestive enzymes using BIOPEP-UWM™ data base tool. The resultant peptides after simulated digestion were evaluated for their toxicity using ToxinPred software. All digestive resistance peptides were found to be non-toxic and displayed favorable functional properties indicating their potential for use in a wide range of food applications, including hydrophobic and hydrophilic systems. Identified peptides were further assessed for their medicinal characteristics by employing SwissADME web-based application. Our findings provide an insight on potential use of undervalued sea cucumber processing discards for functional food product development and natural pharmaceutical ingredients attributed to the oral drug discovery process.

Keywords: sea cucumber by-products; bioinformatics; bioactive peptides; value addition

1. Introduction

Identification of bioactive peptides has evolved over the years from tedious time-consuming conventional processing steps of purification and characterization into the use of bioinformatic tools to discover the potential precursors of bioactive peptides [1,2]. The use of protein databases and computer-based tools to assess food protein sequences has become an effective and feasible method to discover and identify the bioactive peptides [2]. The bioinformatics approach combines biological mass data using computer science, biology, mathematics and statistical analysis methods [3]. These in silico approaches include diversified tools as databases of protein and peptide sequences, web-based applications for predicting the bioactivities and physicochemical properties of proteins and peptides, identifying structure-functional relationships of peptide as well as programs that enable the theoretical hydrolysis of proteins. The latter is done by calculating quantitative descriptors and recommending the use of appropriate enzymes as endopeptidases or exopeptidases to produce potent peptides from native proteins [4]. Furthermore, use of ‘-omics’ techniques could replace the existing ‘trial and error approach’ in peptide purification and activity research. The downstream purification process of bioactive peptides can be accelerated by the integration of in silico methods with ‘-omics’ approach. The bioinformatic tools, including universal protein and peptide data bases (UniProtKB, SwissProt, BIOPEP and PepBank), are employed to obtain high throughput related to in silico protein digestion and peptide prediction information on potent bioactive peptide sequences [1,2]. Therefore, use of bioinformatics is recognized as an effective mining tool to accelerate the process of discovering bioactive peptides encrypted in different types of protein precursors.
In recent years, much attention has been paid to identifying bioactive peptides originating or produced from seafood processing waste [5–7]. It is also identified as an effective bio-refinery approach to address the adverse environmental conditions associated with common waste disposal methods [5,6]. Numerous studies have been conducted for utilizing various marine organisms and their by-products as rich sources of bioactive peptides and essential amino acids [6–8]. However, when compared to other marine fisheries, sea cucumbers remain a largely untapped marine protein resource [9–11]. In particular, Atlantic Sea cucumber Cucumaria frondosa is still considered as an emerging fishery in North Atlantic provinces [9,10]. It is mainly fished for its internal muscle bands and body wall [10,12]. All the other remaining tissues including aquapharyngeal bulb (flower) and internal organs such as digestive tract, gonads, and respiratory tree are discarded as processing waste [11–13]. A limited number of studies have reported the potential of utilizing the Atlantic Sea cucumber by-products as precursor materials for bioactive peptides [14,15]. To the best of our knowledge in silico analysis on hydrolysates prepared from sea cucumber by-products have not been studied to assess their potential as inhibitors of angiotensin converting enzyme (ACE). Furthermore, there are no reports on exploring drug likeliness of sea cucumber derived bioactive peptides.

For the first time, the present study reports the application of in silico tools to comprehensively study peptidomic data of protein hydrolysates prepared from Atlantic Sea cucumber by-products as sources of antioxidant and ACE inhibitory peptides. In addition, the aim of the study was also to predict the drug likeliness of sea cucumber derived multifunctional peptides.

2. Results and Discussion

2.1. Prediction of Bioactive Potential of Identified Peptides from Protein Hydrolysates Samples

Identified peptides from LC-MS/MS analysis were analyzed using “Peptide Ranker (PepRank)” web-based application. PepRank is an in silico tool that predicts the probability of a peptide to be bioactive by ranking them within the range between 0 and 1 [16]. Computational predictions of bioactivity in PepRank generally cover the different classes of bioactive peptides. In addition, it considers the amino acid composition and impact of extracellular status on predictions [17]. Upon submitting the list of identified peptide sequences from each sample, PepRank predicts the probability of the bioactivity of each submitted peptide. The general threshold value is referred as 0.5 and peptides that possess scores above 0.5 are considered bioactive [18]. It is also noteworthy that false positive rates decrease with increasing the threshold values. For example, a false-positive rate of 16% of short peptides at 0.5 threshold will decrease to 6% by increasing the threshold to 0.8. For long chain peptides this will change from 11% to 6% [17]. Furthermore, it may also affect the true-positive rate. Therefore, it is always prudent to select the threshold value carefully based on the purpose of the analysis, i.e., identification of all the true-positives or screening out or reduce the number of false-positives [17,18]. For our study, we selected 0.9 as the threshold value based on suggestion that the probability of a peptide to be bioactive is significantly high when the predicted score is close to 1 [16]. As shown in Table 1, 8 peptides were over 0.9 threshold score in flower whereas 6 peptides were identified from internal organs samples. Among all the predicted values, flower and internal organs shared the same peptide sequence (GPPGPQWPLDF with 0.96) for the highest predicted bioactivity. The predicted bioactive peptides were then analyzed for their specific bioactive potentials with emphasis on antioxidant and ACE inhibitory activities using BIOPEP data base.
Table 1. Bioactive potential of identified peptides according to PEPRANK.

| Sample         | Total Identified Peptides over 0.9 Threshold | PepRank | Peptide Sequence                  |
|----------------|---------------------------------------------|---------|-----------------------------------|
| Flower         | 8                                           | 0.96    | GPPGPQWPLDF                       |
|                |                                             | 0.94    | GPPGPQWPLDF                       |
|                |                                             | 0.94    | GPPGPQWPLDF                       |
|                |                                             | 0.94    | GPPGPQWPLDF                       |
|                |                                             | 0.93    | GPPGPQWPLDF                       |
|                |                                             | 0.92    | GPPGPQWPLDF                       |
|                |                                             | 0.92    | GPPGPQWPLDF                       |
|                |                                             | 0.90    | GPPGPQWPLDF                       |
|                |                                             | 0.90    | GPPGPQWPLDF                       |
| Internal organs| 6                                           | 0.96    | GPPGPQWPLDF                       |
|                |                                             | 0.94    | GPPGPQWPLDF                       |
|                |                                             | 0.93    | GPPGPQWPLDF                       |
|                |                                             | 0.92    | GPPGPQWPLDF                       |
|                |                                             | 0.92    | GPPGPQWPLDF                       |
|                |                                             | 0.90    | GPPGPQWPLDF                       |
|                |                                             | 0.90    | GPPGPQWPLDF                       |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.

2.2. In Silico Predictions of Potential Antioxidative Peptides

BIOPEP-UWM™ data base tool was used to identify the antioxidant potential of highest-ranking peptides. Peptide sequences were analyzed based on the profiles of potential bioactive peptides reported in the literature and databases as well as the frequency of occurrence of fragments with a given activity [19]. Identified peptide sequences were submitted to the BIOPEP as query sequences and selected the “antioxidant activity” as bioactivity of interest. Tables 2 and 3 represent the in silico predictions of antioxidant potential of amino acid sequences found in flower and internal organs, respectively.

According to the BIOPEP-UWM™ data base, 5 out of 8 peptides from flower and 2 out of 6 peptides from internal organs were identified as potential antioxidative peptides. Interestingly, all the three body parts of the sea cucumber shared similar bioactive sequences, namely GPP, WPL and MM. In general, amino acid residues including G (glycine), P (proline), W (tryptophan), L (leucine) and M (methionine) are recognized as some of the most established hydrophobic amino acids associated with antioxidant activity [5,7,20]. For example, tryptophan is an electron-dense aromatic residue that can contribute to the chelation of prooxidant metal ions. Moreover, the indole side chain of tryptophan can scavenge free radicals by electron donation [21]. Similar findings were reported by Zhang et al. [15] in Alcalase-produced peptide fractions from Atlantic Sea cucumber samples. Furthermore, the authors indicated that antioxidant potential of peptides produced using Alcalase was higher than that of trypsin-produced peptides due to the presence of the above-mentioned amino acid residues in their sequences [15]. In addition, the common amino acid sequence found in the sea cucumber body parts, GPPGPQWPLDF, contained phenylalanine (F). Phenylalanine can also act as a hydrogen donor to scavenge free radicals [22]. Presence of hydrophobic and aromatic amino acids is considered as key attributes to the antioxidative property of bioactive peptides [23]. Several antioxidant peptides identified from marine invertebrates including shrimp, jelly fish confer that peptides having most hydrophobic amino acids in their sequences possess strong antioxidant activities, including radical scavenging, reducing power, and inhibition of lipid peroxidation [24]. GP (glycine-proline) sequence and particularly the occurrence of proline (P) in high proportion in the entire peptide enhanced its radical scavenging ability, in addition to the direct contribution of tryptophan [25]. When considering lipid peroxidation, it is presumed that increased lipid solubility of peptides due to the presence of hydrophobic amino acids can facilitate the interaction with radical species [22,24]. Therefore, the current findings support the fact that sea cucumber-derived peptides may have the potential to inhibit the lipid peroxidation process. In addition, the synergism of amino acid residues present in the sequence may...
also contribute to antioxidant properties [24–26]. Therefore, the occurrence of potential bioactive sequences inside the identified peptides may enhance opportunities to identify novel antioxidant sources.

**Table 2.** In silico predictions of potential antioxidative peptides from flower protein hydrolysates.

| Sample    | Peptide Sequence | Name of Peptide       | Activity      | Bioactive Sequence | Location of Fragmentation |
|-----------|------------------|-----------------------|---------------|--------------------|---------------------------|
| Flower    | GPPGPQWPLDF      | Peptide from buckwheat | antioxidative | WPL                | (7–9)                     |
|           | GPPGPRGPTGRMG    | Antioxidative peptide  | antioxidative | GPP                | (1–3)                     |
|           | GPPGPGPGM        | Antioxidative peptide  | antioxidative | GPP                | (1–3)                     |
|           | APDMAFPR         |                       |               |                    |                           |
|           | GGFPGPGG        |                       |               |                    |                           |
|           | GPMMMGMP        | Antioxidative peptide  | antioxidative | MM                 | (5–6)                     |
|           | GPPGASGGLGAGSM  | Antioxidative peptide  | antioxidative | GPP                | (1–3)                     |
|           | GPSGPGGP        | Antioxidative peptide  | antioxidative | GPP                | (4–6)                     |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.

**Table 3.** In silico predictions of potential antioxidative peptides from internal organs hydrolysates.

| Sample     | Peptide Sequence | Name of Peptide       | Activity      | Bioactive Sequence | Location of Fragmentation |
|------------|------------------|-----------------------|---------------|--------------------|---------------------------|
| Internal organs | GPPGPQWPLDF | Peptide from buckwheat | antioxidative | WPL                | (7–9)                     |
|            | GEPFPKF         | Antioxidative peptide  | antioxidative | GP                 | (1–3)                     |
|            | APDMAFPR        |                       |               |                    |                           |
|            | GPPGPGM         |                       |               |                    |                           |
|            | GPMMMGMP        | Antioxidative peptide  | antioxidative | MM                 | (5–6)                     |
|            | DPIFFPS         |                       |               |                    |                           |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, E—Glutamic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.

2.3. In Silico Predictions of Potential ACE Inhibitory Peptides

Computer simulation for the identification of ACE inhibitory activities was conducted using BIOPEP-UWM™ data base tool by selecting the “ACE inhibitory activity” as bioactivity of interest. In silico approaches use chemometrics and information related to sequence homology for understanding and predicting the bioactivity of amino acid sequences submitted to the data base as “query sequence” [27]. According to the findings given in Tables 4 and 5, all selected bioactive peptides in flower and internal organs possess ACE inhibitory active sequences.

**Table 4.** In silico predictions of potential ACE inhibitory active peptides from flower protein hydrolysates.

| Sample | Peptide Sequence | Name of Peptide Appears in the Data Base | Bioactive Sequence | Location of Fragmentation |
|--------|------------------|------------------------------------------|--------------------|---------------------------|
| Flower | GPPGPQWPLDF      | ACE inhibitor from Alaskan pollack skin   | GP                 | (1–2), (4–5)              |
|        |                  | ACE inhibitor from Alaskan pollack skin  | PL                 | (8–9)                     |
|        |                  | ACE inhibitor from wheat gliadin         | PG                 | (3–4)                     |
|        |                  | ACE inhibitor                            | GP                 | (1–3)                     |
|        |                  | ACE inhibitor                            | PP                 | (2–3)                     |
|        |                  | ACE inhibitor                            | PQ                 | (5–6)                     |
|        |                  | ACE inhibitor                            | DF                 | (10–11)                   |
|        |                  | ACE inhibitor                            | PR                 | (5–6)                     |
| GPPGPRGPTGRMG |                  | ACE inhibitor                            | PR                 | (5–6)                     |
Table 4. Cont.

| Sample | Peptide Sequence | Name of Peptide Appears in the Data Base | Bioactive Sequence | Location of Fragmentation |
|--------|------------------|------------------------------------------|-------------------|--------------------------|
|        | ACE inhibitor from Alaskan pollack skin | GP | (1–2), (4–5), (7–8) |
|        | ACE inhibitor | GR | (10–11) |
|        | ACE inhibitor | MG | (12–13) |
|        | ACE inhibitor | TG | (9–10) |
|        | ACE inhibitor | PG | (3–4) |
|        | ACE inhibitor from wheat gliadin | GPP | (1–3) |
|        | ACE inhibitor | PT | (8–9) |
|        | ACE inhibitor | PP | (2–3) |
|        | ACE inhibitor | RG | (6–7) |
|        | ACE inhibitor from Alaskan pollack skin | GPGGPGPGM | (1–2), (4–5), (6–7) |
|        | ACE inhibitor | GR | (10–11) |
|        | ACE inhibitor | MG | (12–13) |
|        | ACE inhibitor | TG | (9–10) |
|        | ACE inhibitor | PG | (3–4) |
|        | ACE inhibitor | PT | (8–9) |
|        | ACE inhibitor | PP | (2–3) |
|        | ACE inhibitor | RG | (6–7) |
|        | ACE inhibitor from Alaskan pollack skin | APDMAFPR | (6–7) |
|        | ACE inhibitor | FP | (6–7) |
|        | ACE inhibitor | PR | (7–8) |
|        | ACE inhibitor | AF | (5–7) |
|        | ACE inhibitor | AP | (1–2) |
|        | ACE inhibitor | DM | (3–4) |
|        | ACE inhibitor from Alaskan pollack skin | GGFGGGPG | (4–5) |
|        | ACE inhibitor from Alaskan pollack skin | GP | (7–8) |
|        | ACE inhibitor | GF | (3–4) |
|        | ACE inhibitor | GG | (2–3), (6–7) |
|        | ACE inhibitor | PG | (5–6), (8–9) |
|        | ACE inhibitor from Alaskan pollack skin | GGFGGGPG | (4–5) |
|        | ACE inhibitor from Alaskan pollack skin | GPGMMGP | (4–5) |
|        | ACE inhibitor | GP | (7–8) |
|        | ACE inhibitor | GM | (3–4) |
|        | ACE inhibitor | GG | (2–3), (6–7) |
|        | ACE inhibitor | PG | (5–6), (8–9) |
|        | ACE inhibitor from Alaskan pollack skin | GPGASGPLGIAAGSM | (7–9) |
|        | ACE inhibitor from Alaskan pollack skin | GPL | (7–9) |
|        | ACE inhibitor from Alaskan pollack skin | PLG | (8–10) |
|        | ACE inhibitor from Alaskan pollack skin | GP | (1–2), (7–8) |
|        | ACE inhibitor from Alaskan pollack skin | PL | (8–9) |
|        | ACE inhibitor from soy hydrolysate | IA | (11–12) |
|        | ACE inhibitor | GI | (10–11) |
|        | ACE inhibitor | GA | (4–5) |
|        | ACE inhibitor | AG | (12–13) |
|        | ACE inhibitor | GS | (13–14) |
|        | ACE inhibitor | SG | (6–7) |
|        | ACE inhibitor | LG | (9–10) |
|        | ACE inhibitor | PG | (3–4) |
|        | ACE inhibitor from wheat gliadin | GPP | (1–3) |
|        | ACE inhibitor | PP | (2–3) |
|        | ACE inhibitor | LGI | (9–11) |
|        | ACE inhibitor | SGP | (6–8) |
|        | ACE inhibitor | AGS | (12–14) |
|        | ACE inhibitor from Alaskan pollack skin | GPGASGPLGIAAGSM | (7–9) |
|        | ACE inhibitor from Alaskan pollack skin | GPL | (7–9) |
|        | ACE inhibitor from Alaskan pollack skin | PLG | (8–10) |
|        | ACE inhibitor from Alaskan pollack skin | GP | (1–2), (7–8) |
|        | ACE inhibitor from Alaskan pollack skin | PL | (8–9) |
|        | ACE inhibitor from soy hydrolysate | IA | (11–12) |
|        | ACE inhibitor | GI | (10–11) |
|        | ACE inhibitor | GA | (4–5) |
|        | ACE inhibitor | AG | (12–13) |
|        | ACE inhibitor | GS | (13–14) |
|        | ACE inhibitor | SG | (6–7) |
|        | ACE inhibitor | LG | (9–10) |
|        | ACE inhibitor | PG | (3–4) |
|        | ACE inhibitor from wheat gliadin | GPP | (1–3) |
|        | ACE inhibitor | PP | (2–3) |
|        | ACE inhibitor | LGI | (9–11) |
|        | ACE inhibitor | SGP | (6–8) |
|        | ACE inhibitor | AGS | (12–14) |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.
Table 5. In silico predictions of potential ACE inhibitory active peptides from internal organs hydrolysates.

| Sample                  | Peptide Sequence   | Name of Peptide                           | Bioactive Sequence | Location of Fragmentation |
|-------------------------|--------------------|--------------------------------------------|--------------------|---------------------------|
| Internal organs         | GPPGQWPLDF         | ACE inhibitor from Alaskan pollack skin     | GP                 | (1–2), (4–5)              |
|                         |                    | ACE inhibitor from Alaskan pollack skin     | PL                 | (8–9)                     |
|                         |                    | ACE inhibitor                               | PG                 | (3–4)                     |
|                         |                    | ACE inhibitor from wheat gliadin            | GPP                | (1–3)                     |
|                         |                    | ACE inhibitor                               | PP                 | (2–3)                     |
|                         |                    | ACE inhibitor                               | PQ                 | (5–6)                     |
|                         |                    | ACE inhibitor                               | DF                 | (10–11)                   |
|                         | GEPFPKF            | ACE inhibitor from Tricholoma giganteum     | GP                 | (1–3)                     |
|                         |                    | ACE inhibitor                               | GE                 | (1–2)                     |
|                         |                    | ACE inhibitor                               | KF                 | (6–7)                     |
|                         |                    | ACE inhibitor                               | PFP                | (3–5)                     |
|                         |                    | ACE inhibitor from Wheat gliadin            | GEP                | (1–3)                     |
|                         |                    | ACE inhibitor                               | GE                 | (1–2)                     |
|                         |                    | ACE inhibitor                               | KP                 | (6–7)                     |
|                         |                    | ACE inhibitor                               | PFP                | (3–5)                     |
|                         | APDMAFPR           | ACE inhibitor                               | FP                 | (7–8)                     |
|                         |                    | ACE inhibitor                               | PR                 | (8–9)                     |
|                         |                    | ACE inhibitor                               | AFP                | (6–8)                     |
|                         |                    | ACE inhibitor                               | AF                 | (6–7)                     |
|                         |                    | ACE inhibitor                               | AP                 | (2–3)                     |
|                         |                    | ACE inhibitor                               | DM                 | (4–5)                     |
|                         | PGGPGGM            | ACE inhibitor from Alaskan pollack skin     | GP                 | (3–4), (5–6)              |
|                         |                    | ACE inhibitor                               | GM                 | (7–8)                     |
|                         |                    | ACE inhibitor                               | GG                 | (2–3)                     |
|                         |                    | ACE inhibitor                               | PG                 | (1–2), (4–5), (6–7)       |
|                         | GPGMMGP            | ACE inhibitor from Alaskan pollack skin     | GP                 | (2–3), (7–8)              |
|                         |                    | ACE inhibitor                               | GM                 | (4–5)                     |
|                         |                    | ACE inhibitor                               | MG                 | (6–7)                     |
|                         |                    | ACE inhibitor                               | PG                 | (3–4)                     |
|                         |                    | ACE inhibitor                               | MM                 | (5–6)                     |
|                         |                    | ACE inhibitor                               | MGP                | (6–8)                     |
|                         | DPIFFPS            | ACE inhibitor                               | FP                 | (5–6)                     |
|                         |                    | ACE inhibitor                               | IF                 | (3–4)                     |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.

It is evident that all active fragments are either dipeptides or tripeptides. Presence of hydrophobic amino acid residues is the crucial structural feature for ACE inhibitory potential [28]. Hydrophobic amino acids including P (proline), M (methionine), L (leucine), I (isoleucine), F (phenylalanine), and A (alanine) were identified in the predicted potent amino acid sequences. In addition, positioning of hydrophobic amino acids or branched chain amino acid residues at the C-terminal of the sequence and N-terminal aliphatic amino acids are some of the major structural features which favors the ACE binding function [29]. These characteristic features were exhibited in predicted sequences of flower and internal organs. The highest number of potential ACE inhibitory dipeptides, and tripeptides (17) were found in sequence GPPGASGPLGIAGSM from flower. Furthermore, all the other predicted ACE inhibitory peptides shared similar structural features, including the presence of hydrophobic amino acid residues in the sequence. In addition, occurrence of consecutive proline-proline dipeptide in the sequence is markedly effective for antihypertensive activities [7]. The effect of proline towards the ACE inhibitory activity associates with its imidazole ring that exhibits strong interaction with the amino acid residues at the active centers of ACE [30]. According to the most recent studies, more than 50% of the identified ACE inhibitory peptides from gelatin hydrolysates had proline residues in the C-terminal position whereas more than 60% had one proline residue in one of the three C-terminal positions [29,30]. Most of the identified peptides in the present study also had this GP sequence at their C-terminal. Almost all predicted ACE inhibitory peptides in sea cucumber protein hydrolysates were found to have the proline residue in each of their sequences. This
further confirms the potential of peptides derived from the North Atlantic Sea cucumber towards ACE inhibition.

However, it has been suggested that ACE inhibitory property of protein hydrolysates could be considered as a collective effect from various peptide chains rather than from a single bioactive peptide [7,29,31]. In addition, it is always recommended to investigate the potential resistance to gastric enzymes of these identified bioactive peptides, once they are expected to exert a beneficial physiological effect after digestion. Thus, all predicted peptides from sea cucumber protein hydrolysates were subjected to in silico simulated gastrointestinal digestion to determine their efficacy upon digestion.

2.4. In Silico Simulated Gastrointestinal (GI) Digestion of Bioactive Peptides

Simulated GI digestion that mimics protein degradation in the stomach and small intestine is considered as a rapid and effective tool to determine the stability of peptides against GI proteases [30]. In this regard, in silico simulated GI digestion is an effective approach to investigate the bioactive potential of any peptide of interest prior to assessing their bioavailability and bioaccessibility in vivo. Thus, selected peptides were subjected to in silico proteolysis simulation with representative digestive enzymes; pepsin (EC 3.4.23.1), trypsin (EC 3.4.21.4) and chymotrypsin (EC 3.4.21.1) using “BIOPEP Enzyme(s) Action” program [19]. The current study predicted the potential of peptides derived from sea cucumber protein hydrolysates as the precursors of peptides with antioxidative or ACE inhibitory properties. Tables 6 and 7 represent the bioactive potential upon GI digestion of peptides derived from flower and internal organs, respectively.

Table 6. Remaining bioactive properties after in silico simulated gastrointestinal digestion of peptides originated from flower protein hydrolysates.

| Sample | Peptide         | Results of Enzyme Action | Location of Released Peptides | Active Fragment Sequence | Location Bioactivity of Identified Peptide |
|--------|-----------------|--------------------------|-------------------------------|-------------------------|------------------------------------------|
| Flower | GPPGQWPLDF      | GPPGPQW—PL—DF            | (1–7), (8–9), (10–11)         | PL                     | (8–9) ACE inhibitor                      |
|        |                 |                          |                               |                         |                                          |
|        | GPPGPRGPTGRMG   | GPPGPR—GPTGR—M—G         | (1–6), (7–11), (12–12), (13–13) | _                      | _ No Antioxidant or ACE inhibitory activity |
|        |                 |                          |                               |                         |                                          |
|        | GPPGPGGM        | _                        | _                             | _                      | _                                        |
|        |                 |                          |                               |                         |                                          |
|        | APDMAFPR        | APDM—AF—PR               | (1–4), (5–6), (7–8)           | PR                     | (5–6) ACE inhibitor                      |
|        |                 |                          |                               |                         |                                          |
|        | GGFPGGPG        | GGF—PGGPG                | (1–3), (4–8)                  | _                      | _ No Antioxidant or ACE inhibitory activity |
|        |                 |                          |                               |                         |                                          |
|        | GPGMGP          | GPGM—M—GP                | (1–4), (5–5), (6–7)           | GP                     | (6-7) ACE inhibitor                      |
|        |                 |                          |                               |                         |                                          |
|        | GPGASGPIAGSM    | GPGASGPL—GIAGSM          | (1–9), (10–15)                | _                      | _ No Antioxidant or ACE inhibitory activity |
|        |                 |                          |                               |                         |                                          |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.
Table 7. Remaining Antioxidant or ACE inhibitory properties after in silico simulated gastrointestinal digestion of peptides originated from internal organs protein hydrolysates.

| Sample          | Peptide            | Results of Enzyme Action | Location of Released Peptides | Active Fragment Sequence | Location | Bioactivity of Identified Peptide                  |
|-----------------|--------------------|--------------------------|-------------------------------|--------------------------|----------|--------------------------------------------------|
| Internal organs | GPPGPQWPLDF        |                          | (1–7), (8–9), (10–11)        | PL (8–9)                 | (10–11)  | ACE inhibitor                                    |
|                 |                    |                          |                               |                          |          | ACE inhibitor                                    |
|                 | GPPGPQW—PL—DF     |                          |                               |                          |          | No Antioxidant or ACE inhibitory activity        |
|                 | GEPFPKF            |                          | (1–4), (5–6), (7–7)          |                         |          |                                                  |
|                 | GEPF—PK—F         |                          |                               |                          |          |                                                  |
|                 | APDMAFPR           |                          | (1–4), (5–6), (7–8)          | PR (7–8)                 | (5–6)    | ACE inhibitor                                    |
|                 | APDM—AF—PR        |                          |                               |                          |          | ACE inhibitor                                    |
|                 | PGDPGPDM           |                          |                               |                          |          |                                                  |
|                 | GPGMMGP            |                          | (1–4), (5–5), (6–7)          | GP (6–7)                 |          | ACE inhibitor                                    |
|                 | GPGM—M—GP         |                          |                               |                          |          |                                                  |
|                 | DPIFFPS            |                          | (1–4), (5–5), (6–7)          |                         |          | No Antioxidant or ACE inhibitory activity        |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, T—Threonine, M—Methionine, A—Alanine, R—Arginine, S—Serine, I—Isoleucine, K—Lysine.

According to the predictions, none of the peptides showed antioxidative potential after the simulated digestion process. This may be due to the scarcity of information in databases related to the potent antioxidative active peptides. It has been suggested that bioinformatics strongly depend on the information included in the data base [1]. However, prediction of releasing ACE inhibitory peptides was found to be similar in all samples. Three peptides (GPPGPQWPLDF, APDMAFPR and GPGMMGP) from flower and internal organs were predicted to release potent ACE inhibitory fragments from their original sequences. Furthermore, frequency of releasing potent ACE inhibitory peptides from each identified peptide was varied as some peptides have more than one active fragment embedded in their sequences. For example, GPPGPQWPLDF sequence was predicted to release two active ACE inhibitory sequences, namely PL and DF, whereas APDMAFPR has the potential to release PR and AF following simulated GI digestion. The release of bioactive peptides was predicted after using the “enzyme(s) action” option of BIOPEP data base (Table 8).

Table 8. In silico hydrolysis performance and physicochemical characteristics of bioactive peptides remaining after simulated in silico digestion.

| Peptide    | Sample          | Active Fragment Sequence | Location | DHt (%) | A_E  | W   |
|------------|-----------------|--------------------------|----------|---------|------|-----|
| GPPGPQWPLDF| flower, internal organs | PL (8–9), (10–11)        | 20       | 0.18    | 0.25 |
| GPPGPQWPLDF|                  | DF                       |          |         |      |
| GPGMMGP    | Flower, internal organs | GP (6–7)                 | 33.33    | 0.14    | 0.14 |
| APDMAFPR   | flower, internal organs | AF (5–6), (7–8)          | 28.57    | 0.25    | 0.33 |

G—Glycine, P—Proline, Q—Glutamine, W—Tryptophan, L—Leucine, D—Aspartic acid, F—Phenylalanine, M—Methionine, A—Alanine, R—Arginine.
Calculated quantitative parameters of proteolysis include theoretical degree of hydrolysis (DHt), the frequency of the release of fragments with a given activity by selected enzymes (AE), and the relative frequency of the release of fragments with a given activity by selected enzymes (W). The DHt values for peptides varied from 11.11 to 33.33%. Among them, GPGMMGP showed the highest efficiency (33.33%) on releasing the bioactive enzymes and GPPGPGNAF was the lowest (11.11%). Descriptors like AE and W directly analyzed the potential bioactivity of sea cucumber derived peptides. The higher AE values suggest the possibility of having higher number of peptides with specific activity. The highest AE value (0.25) was observed in APDMAFPR from flower and internal organs [32]. The other remaining peptide sequences, namely GPPGPQWPLDF and GPGMMGP, were common for all samples and their calculated AE values were 0.18 and 0.14, respectively. The highest relative frequency of the release of fragments with a given activity by selected enzymes (W) was 0.33 in APDMAFPR, followed by GPPGPQWPLDF (0.25). Similar W value (0.14) was observed for GPGMMGP and GPPGPGNAF. It was suggested that W values are considered complimentary to AE values [19]. In addition, W values can be correlated with catalytic specificities and the number of recognition sites in each enzyme [33]. Most of the bioactive fragments remaining after in silico simulated digestion of sea cucumber derived peptides possess either P (proline) or phenylalanine (F) in their dipeptide sequences. The resultant bioactive motifs contain PL (proline-leucine), DF (aspartic acid-phenylalanine), GP (glycine-proline), AF (alanine-phenylalanine) and PR (proline-arginine). Similar findings were reported by Iwaniak et al. [32] in their in silico study of identifying biopeptides from collagen derived from various sources including cow, pig, sheep, chicken, duck, horse, salmon, rainbow trout, goat, rabbit and turkey. Authors reported that all the identified motifs which exhibited ACE inhibitory activity contained proline, phenylalanine, glycine, leucine and arginine. As described earlier, previous studies on ACE inhibitory peptides also revealed that proline residues appear to provide resistance to digestive enzymes. The dipeptide sequences with a C-terminal proline and hydroxyproline were reported to be more bioavailable compared to other amino acid sequences [34]. Specifically, the presence of proline is well documented for its distinct ability for binding to ACE and interestingly, most commercially existing inhibitors bear the proline residue in their sequences [35]. Furthermore, some studies have identified that the presence of hydrophobic amino acids at the penultimate position of C-terminus as being a favorable feature for ACE inhibitory potency [36]. Thus, in silico prediction of generating potent ACE inhibitory peptides from sea cucumber samples may contribute to a better understanding of peptide efficiency before performing in vitro and in vivo experiments. Nevertheless, these findings can be used as a preliminary information on the stability of the sea cucumber derived peptides as well as to help determining the relationship between amino acid composition of peptides and their GI digestion.

2.5. Prediction of Toxicity and Physicochemical Properties of Released Bioactive Peptide Fractions after In Silico Digestion

In silico proteolysis does not guarantee that the resultant peptides with bioactivities are always safe for use in food and pharmaceutical products. In addition, there is a possibility of identifying novel peptides. Therefore, toxicity evaluation has been suggested as a mandatory approach prior to further development of identified motifs [33]. The software ToxinPred was used for predicting the toxicity of peptides as well as their physicochemical properties including hydrophobicity, hydrophilicity, charge, isoelectric point and molecular weight of the released dipeptides. The toxicity of peptides was investigated based on hybrid model of dipeptide composition and motif scanning [37]. According to the model developed using the machine-learning techniques support vector machine (SVM) based on amino acid compositional analysis, residue preferences combined with quantitative matrix-based and motif-based predictions, ToxinPred creates the platform to assess realistic toxicity of peptides [38]. The developed method revealed that valine (V), threonine (T), arginine (R), glutamine (E), methionine (M), leucine (L), lysine (K), isoleucine (I), phenylalanine
(F) and alanine (A) were abundant in non-toxic peptides, whereas cysteine (C), histidine (H) and asparagine (N) were predominant in toxic peptides [38]. Predictions obtained following toxicity analysis show that none of the dipeptides (PL, GF, GP, DF, PR) released from sea cucumber-derived peptide simulated digestion have any potential toxicity. Thus, these findings indicate that sea cucumber-derived peptides can be used as functional food ingredients or nutraceutical products. According to the predictions of ToxinPred, molecular weight of the peptides ranged from 172.20 to 280.29 Da. Out of the five identified ACE inhibitory potent dipeptides obtained from sea cucumber protein hydrolysates, three (PL, GP and AF) had an isoelectric point (pI) of 5.88 with 0 net charge (Table 9).

Table 9. Physicochemical properties and toxicity of bioactive fragments releasing after the simulation in silico digestion.

| Active Fragment Sequence | Prediction | Hydrophobicity | Hydrophilicity | Charge | pI   | Molecular Weight (Da) |
|--------------------------|------------|----------------|----------------|--------|------|----------------------|
| PL                       | Non-toxic  | 0.23           | −0.9           | 0      | 5.88 | 228.31               |
| DF                       | Non-toxic  | −0.05          | 0.25           | −1     | 3.8  | 280.29               |
| GP                       | Non-toxic  | 0.04           | 0              | 0      | 5.88 | 172.20               |
| AF                       | Non-toxic  | 0.43           | −1.5           | 0      | 5.88 | 236.28               |
| PR                       | Non-toxic  | −0.92          | 1.5            | 1      | 10.11| 271.33               |

G—Glycine, P—Proline, L—Leucine, D—Aspartic acid, F—Phenylalanine, A—Alanine, R—Arginine.

The remaining peptides, DF and PR, had negative charge (−1) and positive charge (+1) with a pI of 3.88 and 10.11, respectively. Structural properties, including charge, peptide sequence and low molecular size have been identified as influential characteristics for the bioavailability of food-derived peptides [39]. It has been reported that short chain peptides produced from gelatin hydrolysates have the potential to enter blood stream by crossing the intestinal barriers of humans and exert their bioactivity [40]. Generally, small peptide sequences are less prone to further degradation and possess high bioavailability [41]. In addition, most of the reported potent ACE inhibitory peptides are di- or tripeptides with the ability of binding to the buried active site of ACE [41]. Limited information is available in the literature that discusses correlation between the isoelectric point of peptides and their ACE inhibitory activity. Hydrophobicity values of identified bioactive dipeptides ranged from −0.05 to 0.43, while hydrophilicity values were in the range of −0.9 to 0.25. PL showed the highest hydrophobicity value (0.23) and lowest hydrophilicity value (−0.9). Therefore, the varying physicochemical parameters such as hydrophobicity and hydrophilicity indicate the potential of utilizing the predicted short-chain peptides derived from sea cucumber in a wide range of food systems, including water soluble, lipid soluble as well as in emulsions. In general, ACE inhibitory peptides are expected to exert their functionality in both hydrophilic and hydrophobic systems [42].

2.6. In Silico Analysis of Absorption, Distribution, Metabolism and Excretion (ADME) Profile of Bioactive Peptides Derived from Sea Cucumber Hydrolysates

The trend of using virtual screening for identifying the potential bioactive compounds has become an asset in drug discovery process [43]. Drug development assessments generally include absorption, distribution, and excretion (ADME) parameters. The web-based tool SwissADME provides robust predictive models and primary information for individual parameters important for drug development process [44]. Evaluation of ADME parameters at the initial stage mitigates the pharmacokinetics (i.e., the fate of a therapeutic compound in the organism) related failures in the clinical phase. SwissADME evaluation methods include the analysis of drug-likeness which investigates the probability to be an oral drug [44]. One of the most common and convenient delivery methods of peptide therapeutics is oral administration [45]. The selected criteria in the present study focused on the crucial physicochemical parameters used for drug designing, including number of rotatable bonds (ROTB), number of hydrogen bond acceptors, number of hydrogen bond
donors and water solubility. Furthermore, polarity of the molecule was evaluated using topological polar surface area (TPSA) technique considering sulfur and phosphorus as polar atoms. TPSA is one of the key parameters to estimate the ADME properties [44]. Lipophilicity was analyzed based on the partition coefficient between octanol and water (log Po/w) and it has a vital impact on pharmacokinetics in drug discovery process. Bioavailability score and Lipinski filter were evaluated to assess the qualitative chance for sea cucumber derived peptides to become oral drugs with emphasis on bioavailability and structural characteristics. Lipinski filter is developed on the Lipinski (Pfizer’s) rule of five which is known as the rule of thumb to determine the drug-likeness of a molecule [42]. The main criteria of the rule include less than five hydrogen bond donors (the total number of nitrogen-hydrogen and oxygen-hydrogen bonds), no more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms), molecular mass of less than 500 Da, and an octanol-water partition coefficient (log P) greater than or equal to five. In general, orally active drugs can have only one exemption/violation of these criteria. All these parameters were evaluated on par with the standard captopril. As shown in Table 10, four of the five predicted dipeptides from sea cucumber protein hydrolysates were in accordance with all Lipinski criteria.

Table 10. In silico absorption, distribution, metabolism, excretion (ADME), and physicochemical properties of bioactive peptides.

| Active Fragment Sequence | Physicochemical Properties | Lipophilicity | Drug Likeliness | Pharmacokinetics |
|--------------------------|-----------------------------|---------------|-----------------|-----------------|
|                          | ROTB HBA HBD ESOL           | TPSA (Å²)     | C LogP          | Bioavailability  | Lipinski Filter | GIA  |
| Captopril                | 4 3 1                        | −1.14         | 0.62            | 0.56            | Yes (0)        | High |
| PL                       | 6 4 3                        | Highly soluble | 0.66            | 78.43           | 0.04            | 0.55 Yes (0) High |
| DF                       | 8 6 4                        | Highly soluble | 0.83            | 129.72          | −0.69           | 0.56 Yes (0) High |
| GP                       | 3 4 2                        | Highly soluble | 1.25            | 83.63           | −1.17           | 0.55 Yes (0) High |
| AF                       | 6 4 3                        | Highly soluble | 0.39            | 92.42           | 0.05            | 0.55 Yes (0) High |
| PR                       | 9 5 6                        | Highly soluble | 1.94            | 140.33          | −1.59           | 0.55 Yes (1) Low |

G—Glycine, P—Proline, L—Leucine, D—Aspartic acid, F—Phenylalanine, A—Alanine, R—Arginine.

The remaining dipeptide PR was also in agreement with Lipinski filter criteria with one violation (exceeded the maximum number of hydrogen bond donors (HBD)). Moreover, it has been suggested that compounds with more than 10 rotatable bonds show poor oral bioavailability whereas TPSA value ranging from 20 to 130Å² are suitable for providing high oral bioavailability [42]. All peptides, except PR, exhibited low TPSA values and high gastrointestinal absorbance ability. Lipophilicity and polarity of compounds are crucial to determine the passive gastrointestinal digestion [46]. Furthermore, bioavailability scores of all the identified peptides were similar to that of standard inhibitory drug captopril. Bioavailability radar, a graphical representation of most of the above-mentioned parameters with some additional properties simplifies the evaluation of drug-likeness of a molecule. Six physicochemical properties, including lipophilicity, molecular weight/size, polarity, solubility, saturation, and flexibility of the molecule were displayed in the radar (Figure 1).

**LIPO**, Lipophilicity: −0.7 < XLOGP3 < +5.0; **SIZE**, Molecular size: 150 g/mol < mol. wt. < 500 g/mol; **POLAR**, Polarity: 20 Å² < TPSA < 130 Å²; **INSOLU**, Insolubility: 0 < Log S (ESOL) < 6; **INSATU**, Instauration: 0.25 < Fraction Csp³ < 1; **FLEX**, Flexibility: 0 < Number of rotatable bonds < 9. The colored zone is the suitable physicochemical space for oral bioavailability.
Figure 1. Bioavailability radar of sea cucumber-derived bioactive peptide and ACE inhibitory drug (captopril) based on physicochemical indices ideal for oral bioavailability.

The pink area in the radar represents the favorable range for oral bioavailability which is based on the optimal values for each property. For example, lipophilicity which is indicated by the partition coefficient range between n-octanol and water (log Po/w), should range from −0.7 to +5.0. The molecular weight should be within the size of 150–500 Da and optimal range of TPSA should fall into 20–130 Å². In addition, solubility which is denoted using the descriptor decimal logarithm of the molar solubility in water should not be higher than 6, whereas the fraction of carbons in the sp³ hybridization should not exceed 0.25. The optimum flexibility is accountable for having less than 9 rotatable bonds. However, the crucial determinants related to oral bioavailability of the molecule are flexibility and polarity [42,46]. In our study, except PR, all other dipeptides fall into the optimal range of each parameter (Figure 1). These findings suggest that identified bioactive dipeptides, excluding PR, have excellent conditions for oral bioavailability and better absorption ability in the GI tract. Thus, SwissADME classifiers predictions demonstrate that peptides derived from sea cucumber hydrolysates may possess drug-like properties, similar to standard inhibitory drugs (captopril) and have the potential to be used in
the pharmaceutical industry. However, further experimental validation is needed for confirmation of the predicted properties.

3. Materials and Methods

3.1. Materials

Fresh sea cucumbers (Cucumaria frondosa) were harvested from Northwest and Southeast regions of the St. Pierre Bank (NAFO Division 3Ps), Newfoundland, Canada. Alcalase (2.4 AU/g) and Flavourzyme (1000 LAPU/g) were procured from Novozymes, Bagsvaerd, Denmark. All other chemicals used in the experiments were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada).

3.2. Preparation of Sea Cucumber Protein Hydrolysates

Protein isolation from sea cucumber by-products (i.e., flower and internal organs) was prepared based on isoelectric protein precipitation reported previously [11]. The isolated protein fractions were separately collected and lyophilized prior to hydrolysis. The protein hydrolysates were then prepared according to the method described by Ambigaipalan and Shahidi [7]. The extracted protein isolates from flower (FL) and internal organs (IN) of Atlantic Sea cucumbers were hydrolyzed by sequential addition of Alcalase (AL, 0.3 AU/g) and Flavourzyme (F, 50 LAPU/g) based on the findings of Senadheera et al. [11]. These enzymes are very common in industrial production due to their favorable operational conditions. Upon completion of the incubation period, reactions were terminated by heating the mixture at 90 °C for 10 min to inactivate the enzyme and samples was then freeze-dried until the time of analysis.

3.3. LC-MS/MS Analysis

LC-MS/MS analysis was carried out at the Analytics, Robotics and Chemical Biology Centre (SPARC BioCentre), the Hospital for Sick Children, Toronto, ON, Canada using—Exactive Orbitrap analyzer outfitted with a nanospray source and EASY-nLC nano-LC system (Thermo Fisher, San Jose, CA, USA), as reported by Udenigwe et al. [47] PEAKS X+ software (Bioinformatic Solutions, Waterloo, ON, Canada) was used to perform the data analysis.

3.4. In Silico Prediction of Bioactive Potential of Identified Peptides from Protein Hydrolysate Samples

Peptides identified using PEAKS X+ software were further analyzed for their bioactive potential using in silico tools. Peptides were screened according to their bioactive potential using PepRank (http://bioware.ucd.ie/~compass/biowareweb/ (accessed on 27 September 2020)), which predicts the probability (between 0 and 1) of the peptide being bioactive, as described by Mooney et al. [17]. The threshold of 0.9 was selected to reduce the number of false positives. Selected peptides were analyzed for their bioactive properties related to antioxidant and antihypertensive activities using BIOPEP-UWM™ database (http://www.uwm.edu.pl/biochemia/index.php/en/biopep (accessed on 27 September 2020)) of bioactive peptides. The identified sequences with ACE inhibitory peptides were subjected to in silico hydrolysis using the enzyme(s) action feature of BIOPEP-UWM™ by employing pepsin (EC 3.4.23.1), trypsin (EC 3.4.21.4) and chymotrypsin (EC 3.4.21.1) as representative digestive enzymes as described by Ji et al. [42].

3.5. Toxicity and Physicochemical Properties of Bioactive Peptides Released after in Silico Proteolysis

The potential toxicity, hydrophobicity, hydrophilicity, charge, isoelectric point and molecular weight of the peptides released after simulated digestive proteolysis were predicted using ToxinPred (https://webs.iiitd.edu.in/raghava/toxinpred/index.html (accessed on 2 October 2020)) web-based application according to the method described by Gupta et al. [38].
3.6. In Silico Analysis of Absorption, Distribution, Metabolism and Excretion (ADME) Profile of Bioactive Peptides

In silico analysis of drug-likeliness for identified sea cucumber derived-peptides was evaluated based on absorption, distribution, metabolism and excretion parameters using SwissADME tool (http://www.swissadme.ch/index.php# (accessed on 20 October 2020)) as explained by Daina et al. [44].

4. Conclusions

Based on the above, findings of this study indicate that bioinformatic approach can effectively evaluate the bioactive potential and physicochemical properties of peptides encrypted in sea cucumber by-products proteome. The current findings also provide an important consideration and a direction that can lead to utilize the undervalued sea cucumber by-products as precursor materials to generate oral therapeutic ingredients. Thus, the results of in silico analysis demonstrated that sea cucumber derived peptides present great potential for the development of nutraceutical products. However, the virtual predictions and simulations should be validated using structure-functional analysis and in vivo approaches for confirmation of bioactive properties.

Author Contributions: Conceptualization, T.R.L.S., D.D. and F.S.; methodology, T.R.L.S. and A.H.; software, T.R.L.S.; validation, T.R.L.S.; formal analysis, T.R.L.S.; investigation, T.R.L.S.; resources, T.R.L.S., A.H., D.D. and F.S.; data curation, T.R.L.S.; writing—original draft preparation, T.R.L.S.; writing—review and editing, T.R.L.S., A.H., D.D. and F.S.; visualization, T.R.L.S. and A.H.; supervision, D.D. and F.S.; project administration, D.D. and F.S.; funding acquisition, D.D. and F.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Natural Sciences and Engineering Research Council (NSERC) of Canada (RGPIN-2015-06121 and RGPIN-2016-04468).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The authors wish to thank Chibuike C. Udenigwe for his guidance for the in silico studies and SPARC BioCentre (Molecular Analysis), The Hospital for Sick Children, Toronto, Canada for performing LC/MS analysis.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Udenigwe, C.C. Bioinformatics approaches, prospects and challenges of food bioactive peptide research. Trends Food Sci. Technol. 2014, 36, 137–143. [CrossRef]
2. Agyei, D.; Ongkudon, C.M.; Wei, C.Y.; Chan, A.S.; Danquah, M.K. Bioprocess challenges to the isolation and purification of bioactive peptides. Food Bioprod. Process. 2016, 98, 244–256. [CrossRef]
3. Tu, M.; Cheng, S.; Lu, W.; Du, M. Advancement and prospects of bioinformatics analysis for studying bioactive peptides from food-derived protein: Sequence, structure, and functions. TrAC Trends Anal. Chem. 2018, 105, 7–17. [CrossRef]
4. Kandemir-Cavas, C.; Pérez-Sanchez, H.; Mert-Ozupek, N.; Cavas, L. In Silico analysis of bioactive peptides in invasive sea grass Halophila stipulacea cagin. Cells 2019, 8, 557. [CrossRef]
5. Shahidi, F.; Ambigaipalan, P. Novel functional food ingredients from marine sources. Curr. Opin. Food Sci. 2015, 2, 123–129. [CrossRef]
6. Liu, Y.; Ramakrishnan, V.V.; Dave, D. Enzymatic hydrolysis of farmed atlantic salmon by-products: Investigation of operational parameters on extracted oil yield and quality. Process Biochem. 2020, 100, 10–19. [CrossRef]
7. Ambigaipalan, P.; Shahidi, F. Bioactive peptides from shrimp shell processing discards: Antioxidant and biological activities. J. Funct. Foods 2017, 34, 7–17. [CrossRef]
8. Hossain, A.; Dave, D.; Shahidi, F. Antioxidant potential of sea cucumbers and their beneficial effects on human health. Mar. Drugs 2022, 20, 521. [CrossRef]
9. Senadheera, T.R.L.; Dave, D.; Shahidi, F. Sea cucumber derived type I collagen: A comprehensive review. Mar. Drugs 2020, 18, 471. [CrossRef]
10. Hossain, A.; Dave, D.; Shahidi, F. Northern sea cucumber (Cucumaria Frondosa): A potential candidate for functional food, nutraceutical, and pharmaceutical sector. Mar. Drugs 2020, 18, 274. [CrossRef]
11. Senadheera, T.R.L.; Dave, D.; Shahidi, F. Antioxidant potential and physicochemical properties of protein hydrolysates from body parts of north atlantic sea cucumber (Cucumaria frondosa). Food Prod. Process. Nutr. 2021, 3, 3. [CrossRef]
12. Hossain, A.; Dave, D.; Shahidi, F. Effect of high-pressure processing (HPP) on phenolics of North Atlantic sea cucumber (Cucumaria frondosa). J. Agric. Food Chem. 2022, 70, 3489–3501. [CrossRef]
13. Hossain, A.; Yeo, J.D.; Dave, D.; Shahidi, F. Phenolic compounds and antioxidant capacity of sea cucumber (Cucumaria frondosa) processing discards as affected by high-pressure processing (HPP). Antioxidants 2022, 11, 337. [CrossRef]
14. Liu, L.; Yang, K.; Zheng, L.; Zhao, M.; Sun, W.; Zhu, Q.; Liu, S. Anti-aging effect of sea cucumber (Cucumaria frondosa) hydrolysate on fruit flies and d-galactose-induced aging mice. J. Funct. Foods 2018, 47, 11–18. [CrossRef]
15. Zhang, Y.; He, S.; Bonneil, E.; Simpson, B.K. Generation of antioxidative peptides from Atlantic sea cucumber using Alcalase versus trypsin: In vitro activity, de novo sequencing, and in silico docking for in vivo function prediction. Food Chem. 2020, 306, 125581. [CrossRef]
16. Garg, S.; Apostolopoulos, V.; Nurgali, K.; Mishra, V.K. Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. J. Funct. Foods 2018, 41, 34–40. [CrossRef]
17. Mooney, C.; Haslam, N.J.; Pollastry, G.; Shields, D.C. Towards the improved discovery and design of functional peptides: Common features of diverse classes permit generalized prediction of bioactivity. PLoS ONE 2012, 7, e45012. [CrossRef]
18. Mooney, C.; Haslam, N.J.; Holton, T.A.; Pollastry, G.; Shields, D.C. PeptideLocator: Prediction of bioactive peptides in protein sequences. Bioinformatics 2013, 29, 1120–1126. [CrossRef]
19. Minkiewicz, P.; Iwaniak, A.; Darewicz, M. BIOPEP-UWM database of bioactive peptides: Current opportunities. Int. J. Mol. Sci. 2019, 20, 5978. [CrossRef]
20. Acquah, C.; Di Stefano, E.; Udenigwe, C.C. Role of hydrophobicity in food peptide functionality and bioactivity. J. Food Bioact. 2018, 4, 88–98. [CrossRef]
21. Shahidi, F.; Zhong, Y. Bioactive peptides. J. AOAC Int. 2008, 91, 914–931. [CrossRef]
22. SabeeNA Farvin, K.H.; Andersen, L.L.; Otte, J.; Nielsen, H.H.; Jessen, F.; Jacobsen, C. Antioxidant activity of cod (Gadus Morhua) protein hydrolysates: Fractionation and characterisation of peptide fractions. Food Chem. 2016, 204, 409–419. [CrossRef]
23. Samaranayaka, A.G.P.; Li-Chan, E.C.Y. Food-derived peptidic antioxidants: A review of their production, assessment, and potential applications. Food Chem. 2011, 3, 229–254. [CrossRef]
24. Chai, T.T.; Law, Y.C.; Wong, F.C.; Kim, S.K. Enzyme-assisted discovery of antioxidative peptides from edible marine invertebrates: A review. Mar. Drugs 2017, 15, 42. [CrossRef]
25. Zhou, X.; Wang, C.; Jiang, A. Antioxidant peptides isolated from sea cucumber Stichopus japonicus. Eur. Food Res. Technol. 2012, 234, 441–447. [CrossRef]
26. Wong, F.C.; Xiao, J.; Ong, M.G.L.; Pang, M.J.; Wong, S.J.; Teh, L.K.; Chai, T.T. Identification and characterization of antioxidant peptides from hydrolysate of blue-spotted stingray and their stability against thermal, pH and simulated gastrointestinal digestion treatments. Food Chem. 2019, 271, 614–622. [CrossRef]
27. Ageyi, D.; Tsopmo, A.; Udenigwe, C.C. Bioinformatics and peptidomics approaches to the discovery and analysis of food-derived bioactive peptides. Anal. Bioanal. Chem. 2018, 410, 3463–3472. [CrossRef]
28. Udenigwe, C.C.; Aluko, R.E. Food protein-derived bioactive peptides: Production, processing, and potential health benefits. J. Food Sci. 2012, 77, R11–R24. [CrossRef]
29. Ambigaipalan, P.; Al-Khalifa, A.S.; Shahidi, F. Antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities of date seed protein hydrolysates prepared using Alcalase, Flavourzyme and Thermolysin. J. Funct. Foods 2015, 18, 1125–1137. [CrossRef]
30. O’Keeffe, M.B.; Norris, R.; Alashi, M.A.; Aluko, R.E.; FitzGerald, R.J. Peptide identification in a porcine gelatin prolyl endopeptidase hydrolysate with angiotensin converting enzyme (ace) inhibitory and hypotensive activity. J. Funct. Foods 2017, 34, 77–88. [CrossRef]
31. Ambigaipalan, P.; Al-Khalifa, A.S.; Shahidi, F. Antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities of date seed protein hydrolysates prepared using Alcalase, Flavourzyme and Thermolysin. J. Funct. Foods 2015, 18, 1125–1137. [CrossRef]
32. Iwaniak, A.; Minkiewicz, P.; Pliszka, M.; Mogut, D.; Darewicz, M. Characteristics of biopeptides released in silico from collagens processing discards as affected by high-pressure processing (HPP). Antioxidants 2022, 11, 337. [CrossRef]
33. Nwachukwu, I.D.; Aluko, R.E. Structural and functional properties of food protein-derived antioxidant peptides. J. Food Biochem. 2019, 43, e12761. [CrossRef]
34. Iwaniak, A.; Minkiewicz, P.; Pliszka, M.; Mogut, D.; Darewicz, M. Characteristics of biopeptides released in silico from collagens using quantitative parameters. Foods 2020, 9, 965. [CrossRef]
35. Ji, D.; Udenigwe, C.C.; Ageyi, D. Antioxidant peptides encrypted in flaxseed proteome: An in silico assessment. Food Sci. Hum. Wellness 2019, 8, 306–314. [CrossRef]
36. Neves, A.C.; Harnedy, P.A.; O’Keeffe, M.B.; FitzGerald, R.J. Bioactive peptides from Atlantic salmon (Salmo Salar) with angiotensin converting enzyme and dipeptidyl peptidase IV inhibitory, and antioxidant activities. Food Chem. 2017, 218, 396–405. [CrossRef]
37. Wu, J.; Aluko, R.E.; Nakai, S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: Quantitative structure-activity relationship study of di- and tripeptides. J. Agric. Food Chem. 2006, 54, 732–738. [CrossRef]
38. Yao, S.; Ageyi, D.; Udenigwe, C.C. Structural basis of bioactivity of food peptides in promoting metabolic health. In Advances in Food and Nutrition Research, 1st ed.; Toldrá, F., Ed.; Elsevier Inc.: Cambridge, MA, USA, 2018; Volume 84, pp. 145–181.
39. Lafarga, T.; O’Connor, P.; Hayes, M. Identification of novel dipeptidyl peptidase-IV and angiotensin-I- converting enzyme inhibitory peptides from meat proteins using in silico analysis. Peptides 2014, 59, 53–62. [CrossRef]
40. Gupta, S.; Kapoor, P.; Chaudhary, K.; Gautam, A.; Kumar, R.; Raghava, G.P.S. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE 2013, 8, e73957. [CrossRef]
39. Sun, X.; Acquah, C.; Aluko, R.E.; Udenigwe, C.C. Considering food matrix and gastrointestinal effects in enhancing bioactive peptide absorption and bioavailability. *J. Funct. Foods* 2020, 64, 103680. [CrossRef]

40. Iwai, K.; Hasegawa, T.; Taguchi, Y.; Morimatsu, F.; Sato, K.; Nakamura, Y.; Higashi, A.; Kido, Y.; Nakabo, Y.; Ohutsuki, K. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. *J. Agric. Food Chem.* 2005, 53, 6531–6536. [CrossRef]

41. Ryder, K.; Bekhit, A.E.D.; McConnell, M.; Carne, A. Towards generation of bioactive peptides from meat industry waste proteins: Generation of peptides using commercial microbial Proteases. *Food Chem.* 2016, 208, 42–50. [CrossRef]

42. Ji, D.; Xu, M.; Udenigwe, C.C.; Agyei, D. Physicochemical characterisation, molecular docking, and drug-likeness evaluation of hypotensive peptides encrypted in flaxseed proteome. *Curr. Res. Food Sci.* 2020, 3, 41–50. [CrossRef] [PubMed]

43. Geromichalos, G.D. Virtual screening strategies and application in drug designing. *Drug Des.* 2012, 2, 1000e109. [CrossRef]

44. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* 2017, 7, 42717. [CrossRef] [PubMed]

45. Yap, P.G.; Gan, C.Y. In Vivo Challenges of anti-diabetic peptide therapeutics: Gastrointestinal stability, toxicity and allergenicity. *Trends Food Sci. Technol.* 2020, 105, 161–175. [CrossRef]

46. Daina, A.; Zoete, V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. *Chem. Med. Chem.* 2016, 11, 1117–1121. [CrossRef]

47. Udenigwe, C.C.; Udechukwu, M.C.; Yiridoe, C.; Gibson, A.; Gong, M. Antioxidant mechanism of potato protein hydrolysates against in vitro oxidation of reduced glutathione. *J. Funct. Foods* 2016, 20, 195–203. [CrossRef]